CX NEWS
MDR will be “the most devastating thing to happen to European healthcare since WW2”
Speaking at the Charing Cross Symposium 2019, Jeffrey Jump (Nyon, Switzerland), outlines the impact of the Medical Device Regulations (MDR), which he believes will be “the most devastating thing to happen to European healthcare [...]
Intra-arterial calcification poses “one of the biggest challenges” for endovascular therapy
Andrew Holden (Auckland, New Zealand) provides perspective on the first results from the Disrupt PAD III observational registry that were presented at the Charing Cross International Symposium 2019. This large registry is designed to evaluate [...]
Highlights from the CX 2019 session, Paclitaxel: The last word
The 2019 Charing Cross Symposium (CX; 15–18 April, London, UK) featured an in-depth highlight session on the paclitaxel controversy. With the US FDA Circulatory System Devices Panel Meeting set to take place [...]
With CoveredSeal, Valiant Navion™ offers physicians the “best of both worlds” for TEVAR procedures
Paul Hayes (Cambridge, UK), Frank Arko (Charlotte, USA) and Fabio Verzini (Turin, Italy) discuss the Valiant Navion™ (Medtronic) live thoracic endovascular aortic repair (TEVAR) case at Charing Cross 2019, which demonstrated the use of the [...]
With focal dissection repair, the Tack Endovascular System “returns control to the operator”
Andrew Holden (Auckland, New Zealand) and Peter Schneider (San Francisco, USA) discuss the Tack Endovascular System (Intact Vascular) and its impact on below the knee and above the knee procedures at the Charing Cross Symposium [...]
Durability of endovascular aneurysm repair and the NICE guidelines
A CX 2019 special session highlighted the durability of endovascular aneurysm repair (EVAR) and the implications of the UK National Institute for Health and Care Excellence (NICE) draft aortic aneurysm guidelines. The final publication [...]